These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

757 related articles for article (PubMed ID: 29432077)

  • 21. The oncolytic adenovirus Delta-24-RGD in combination with ONC201 induces a potent antitumor response in pediatric high-grade and diffuse midline glioma models.
    de la Nava D; Ausejo-Mauleon I; Laspidea V; Gonzalez-Huarriz M; Lacalle A; Casares N; Zalacain M; Marrodan L; García-Moure M; Ochoa MC; Tallon-Cobos AC; Hernandez-Osuna R; Marco-Sanz J; Dhandapani L; Hervás-Corpión I; Becher OJ; Nazarian J; Mueller S; Phoenix TN; van der Lugt J; Hernaez M; Guruceaga E; Koschmann C; Venneti S; Allen JE; Dun MD; Fueyo J; Gomez-Manzano C; Gallego Perez-Larraya J; Patiño-García A; Labiano S; Alonso MM
    Neuro Oncol; 2024 Aug; 26(8):1509-1525. PubMed ID: 38554031
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A phase I trial of intratumoral administration of recombinant oncolytic adenovirus overexpressing HSP70 in advanced solid tumor patients.
    Li JL; Liu HL; Zhang XR; Xu JP; Hu WK; Liang M; Chen SY; Hu F; Chu DT
    Gene Ther; 2009 Mar; 16(3):376-82. PubMed ID: 19092859
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Survivin-driven and fiber-modified oncolytic adenovirus exhibits potent antitumor activity in established intracranial glioma.
    Ulasov IV; Zhu ZB; Tyler MA; Han Y; Rivera AA; Khramtsov A; Curiel DT; Lesniak MS
    Hum Gene Ther; 2007 Jul; 18(7):589-602. PubMed ID: 17630837
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Preclinical And Clinical Development Of Oncolytic Adenovirus For The Treatment Of Malignant Glioma.
    Kiyokawa J; Wakimoto H
    Oncolytic Virother; 2019; 8():27-37. PubMed ID: 31750274
    [TBL] [Abstract][Full Text] [Related]  

  • 25. ICOVIR-5 shows E2F1 addiction and potent antiglioma effect in vivo.
    Alonso MM; Cascallo M; Gomez-Manzano C; Jiang H; Bekele BN; Perez-Gimenez A; Lang FF; Piao Y; Alemany R; Fueyo J
    Cancer Res; 2007 Sep; 67(17):8255-63. PubMed ID: 17804740
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Oncolytic H-1 Parvovirus Shows Safety and Signs of Immunogenic Activity in a First Phase I/IIa Glioblastoma Trial.
    Geletneky K; Hajda J; Angelova AL; Leuchs B; Capper D; Bartsch AJ; Neumann JO; Schöning T; Hüsing J; Beelte B; Kiprianova I; Roscher M; Bhat R; von Deimling A; Brück W; Just A; Frehtman V; Löbhard S; Terletskaia-Ladwig E; Fry J; Jochims K; Daniel V; Krebs O; Dahm M; Huber B; Unterberg A; Rommelaere J
    Mol Ther; 2017 Dec; 25(12):2620-2634. PubMed ID: 28967558
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Oncolytic virotherapy for the treatment of pediatric brainstem gliomas.
    Gállego Pérez-Larraya J; García-Moure M; Alonso MM
    Rev Neurol (Paris); 2023 Jun; 179(5):475-480. PubMed ID: 37061388
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Oncolytic Adenovirus and Tumor-Targeting Immune Modulatory Therapy Improve Autologous Cancer Vaccination.
    Jiang H; Rivera-Molina Y; Gomez-Manzano C; Clise-Dwyer K; Bover L; Vence LM; Yuan Y; Lang FF; Toniatti C; Hossain MB; Fueyo J
    Cancer Res; 2017 Jul; 77(14):3894-3907. PubMed ID: 28566332
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Delta-24-RGD combined with radiotherapy exerts a potent antitumor effect in diffuse intrinsic pontine glioma and pediatric high grade glioma models.
    Martinez-Velez N; Marigil M; García-Moure M; Gonzalez-Huarriz M; Aristu JJ; Ramos-García LI; Tejada S; Díez-Valle R; Patiño-García A; Becher OJ; Gomez-Manzano C; Fueyo J; Alonso MM
    Acta Neuropathol Commun; 2019 Apr; 7(1):64. PubMed ID: 31036068
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Oncolytic adenovirus in treating malignant ascites: A phase II trial and longitudinal single-cell study.
    Zhang Y; Qian L; Chen K; Gu S; Meng Z; Wang J; Li Y; Wang P
    Mol Ther; 2024 Jun; 32(6):2000-2020. PubMed ID: 38659226
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Oncolytic adenovirus Delta-24-RGD induces a widespread glioma proteotype remodeling during autophagy.
    González-Morales A; Zabaleta A; García-Moure M; Alonso MM; Fernández-Irigoyen J; Santamaría E
    J Proteomics; 2019 Mar; 194():168-178. PubMed ID: 30503830
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immune Activity and Response Differences of Oncolytic Viral Therapy in Recurrent Glioblastoma: Gene Expression Analyses of a Phase IB Study.
    Miller KE; Cassady KA; Roth JC; Clements J; Schieffer KM; Leraas K; Miller AR; Prasad N; Leavenworth JW; Aban IB; Whitley RJ; Gillespie GY; Mardis ER; Markert JM
    Clin Cancer Res; 2022 Feb; 28(3):498-506. PubMed ID: 35105718
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeting brain tumor stem cells with oncolytic adenoviruses.
    Alonso MM; Jiang H; Gomez-Manzano C; Fueyo J
    Methods Mol Biol; 2012; 797():111-25. PubMed ID: 21948473
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Phase I clinical trial of EUS-guided intratumoral injection of the oncolytic virus, HF10 for unresectable locally advanced pancreatic cancer.
    Hirooka Y; Kasuya H; Ishikawa T; Kawashima H; Ohno E; Villalobos IB; Naoe Y; Ichinose T; Koyama N; Tanaka M; Kodera Y; Goto H
    BMC Cancer; 2018 May; 18(1):596. PubMed ID: 29801474
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Integrin targeted oncolytic adenoviruses Ad5-D24-RGD and Ad5-RGD-D24-GMCSF for treatment of patients with advanced chemotherapy refractory solid tumors.
    Pesonen S; Diaconu I; Cerullo V; Escutenaire S; Raki M; Kangasniemi L; Nokisalmi P; Dotti G; Guse K; Laasonen L; Partanen K; Karli E; Haavisto E; Oksanen M; Karioja-Kallio A; Hannuksela P; Holm SL; Kauppinen S; Joensuu T; Kanerva A; Hemminki A
    Int J Cancer; 2012 Apr; 130(8):1937-47. PubMed ID: 21630267
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetic study of neural stem cell-based cell carrier for oncolytic virotherapy: targeted delivery of the therapeutic payload in an orthotopic brain tumor model.
    Thaci B; Ahmed AU; Ulasov IV; Tobias AL; Han Y; Aboody KS; Lesniak MS
    Cancer Gene Ther; 2012 Jun; 19(6):431-42. PubMed ID: 22555507
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Irradiation enhances the therapeutic effect of the oncolytic adenovirus XVir-N-31 in brain tumor initiating cells.
    Czolk R; Schwarz N; Koch H; Schötterl S; Wuttke TV; Holm PS; Huber SM; Naumann U
    Int J Mol Med; 2019 Oct; 44(4):1484-1494. PubMed ID: 31432139
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Human bone marrow-derived mesenchymal stem cells for intravascular delivery of oncolytic adenovirus Delta24-RGD to human gliomas.
    Yong RL; Shinojima N; Fueyo J; Gumin J; Vecil GG; Marini FC; Bogler O; Andreeff M; Lang FF
    Cancer Res; 2009 Dec; 69(23):8932-40. PubMed ID: 19920199
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase 1 clinical trial of intratumoral reovirus infusion for the treatment of recurrent malignant gliomas in adults.
    Kicielinski KP; Chiocca EA; Yu JS; Gill GM; Coffey M; Markert JM
    Mol Ther; 2014 May; 22(5):1056-62. PubMed ID: 24553100
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A phase I trial of intratumoral administration of reovirus in patients with histologically confirmed recurrent malignant gliomas.
    Forsyth P; Roldán G; George D; Wallace C; Palmer CA; Morris D; Cairncross G; Matthews MV; Markert J; Gillespie Y; Coffey M; Thompson B; Hamilton M
    Mol Ther; 2008 Mar; 16(3):627-32. PubMed ID: 18253152
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 38.